FIB992

Asset

Inhibits a novel kinase target in the matrix stiffness pathway, decreasing secretion of profibrotic cytokines.

Stage
Preclinical
Modality
Small molecule
Target
Not known
1
Indication
0
Trials
1
Developer

Indications

1

In the full profile

  • Owner and partners1

Every asset’s record: target, stage, trials and the evidence behind it.

See Pro

Assets